Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 Nov 29;6(1):29–39. doi: 10.1002/psp4.12140

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2016 The Authors CPT: Pharmacometrics & Systems Pharmacology published by Wiley Periodicals, Inc. on behalf of American Society for Clinical Pharmacology and Therapeutics

This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

PMC Copyright notice

(a) Median response rates at week 28 for the different response categories of 1,000 simulated trials, each with 10,000 patients (mixture model). Median simulated response rates for patients whose tumor is positive for programmed death receptor 1 ligand 1 (PD‐L1) at week 24 for dose schedules ranging from 1 mg/kg every 3 weeks (Q3W) to 10 mg/kg every 2 weeks (Q2W), using the consolidated model structure; (b) ipilimumab‐pretreated patients; and (c) ipilimumab‐naive patients. Error bars represent the 90% confidence intervals around the estimates. Response is defined as change from baseline (CFB) ≤−30%; stable is defined as CFB −30 to −20%; progression is defined as CFB ≥20%. CR, complete response; PD, progressive disease; PR, partial response; SD, stable disease.